Modeling the Kinetics of Digoxin Absorption: Enhancement by P-Glycoprotein Inhibition

被引:12
|
作者
Weiss, Michael [1 ,2 ]
Sermsappasuk, Pakawadee [2 ]
Siegmund, Werner [3 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, D-06097 Halle, Saale, Germany
[2] Naresuan Univ, Fac Pharmaceut Sci, Phitsanulok, Thailand
[3] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Div Clin Pharmacol, Greifswald, Germany
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 52卷 / 03期
关键词
P-glycoprotein inhibition; digoxin; bioavailability; absorption rate; population pharmacokinetics; ORAL BIOAVAILABILITY; PHARMACOKINETICS;
D O I
10.1177/0091270010396711
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An increase in the area under the curve (AUC) after oral digoxin due to coadministration of drugs known as P-glycoprotein (P-gp) inhibitors has been reported in several studies, but there is very little information on the rate of absorption after P-gp inhibition. Based on an inverse Gaussian density absorption model and using a population approach, the authors reanalyzed data showing an increase in oral digoxin AUC in healthy volunteers after coadministration of talinolol. The model fitted the data well, and the results revealed that the maximum rate of digoxin absorption increased nearly 2-fold, whereas bioavailability increased only by 21%. It is concluded that the increase in the rate of absorption seems to be a better indicator of intestinal P-gp inhibition than the increase in extent of absorption. Furthermore, the authors use a simulation study to demonstrate the ability of the method to estimate bioavailability based on the population characteristics of digoxin disposition kinetics obtained from a different group of healthy volunteers.
引用
收藏
页码:381 / 387
页数:7
相关论文
共 50 条
  • [21] Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
    Hongjian Zhang
    Ming Yao
    Richard A. Morrison
    Saeho Chong
    Archives of Pharmacal Research, 2003, 26 : 768 - 772
  • [22] Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin
    Ghanem, Carolina I.
    Gomez, Paula C.
    Arana, Maria C.
    Perassolo, Maria
    Carpini, Griselda Delli
    Luquita, Marcelo G.
    Veggi, Luis M.
    Catania, Viviana A.
    Bengochea, Laura A.
    Mottino, Aldo D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (03): : 1146 - 1152
  • [23] Commonly used surfactant, tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats
    Zhang, HJ
    Yao, M
    Morrison, RA
    Chong, SH
    ARCHIVES OF PHARMACAL RESEARCH, 2003, 26 (09) : 768 - 772
  • [24] The involvement of P-glycoprotein in berberine absorption
    Pan, GY
    Wang, GJ
    Liu, XD
    Fawcett, JP
    Xie, YY
    PHARMACOLOGY & TOXICOLOGY, 2002, 91 (04): : 193 - 197
  • [25] Impact of P-glycoprotein on clopidogrel absorption
    Taubert, Dirk
    von Beckerath, Nicolas
    Grimberg, Gundula
    Lazar, Andreas
    Jung, Norma
    Goeser, Tobias
    Kastrati, Adnan
    Schoemig, Albert
    Schoemig, Edgar
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (05) : 486 - 501
  • [26] Saquinavir absorption: Role of P-glycoprotein
    Back, D
    Eagling, V
    Profit, L
    AIDS, 1998, 12 : S31 - S31
  • [27] Kinetics of the P-glycoprotein, the multidrug transporter
    Stein, WD
    EXPERIMENTAL PHYSIOLOGY, 1998, 83 (02) : 221 - 232
  • [28] Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding
    Seelig, Anna
    Gerebtzoff, Gregori
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (05) : 733 - 752
  • [29] Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
    Kono, Yusuke
    Kawahara, Iichiro
    Shinozaki, Kohei
    Nomura, Ikuo
    Marutani, Honoka
    Yamamoto, Akira
    Fujita, Takuya
    PHARMACEUTICS, 2021, 13 (03)
  • [30] Vitamin E formulation affects digoxin absorption by inhibiting P-glycoprotein (P-gp) in humans.
    Chan, L
    Humma, LM
    Schriever, CA
    Fahsingbauer, LA
    Dominguez, CP
    Baum, CL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P95 - P95